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Abstract. previous studies have suggested that metastasis 
tumour suppressor-1 (mtSS1) plays a key role in cancer 
metastasis. Firstly, in this study we assessed mtSS1 expres-
sion levels in prostate cancer cell lines to reveal any changes 
in cell properties. Secondly, we aimed to clarify the cellular 
function of mtSS1 in prostate cancer cells. mtSS1 expres-
sion levels were assessed in different types of cancer cell lines 
through the RT-PCR analysis technique. The influence of 
mtSS1 was further examined via biological overexpression 
and knockdown in the prostate cancer cell lines. two prostate 
cell lines were chosen for either knockdown or overexpres-
sion of the mtSS1 gene. the overexpression of mtSS1 in 
PC-3 human prostate cancer cells significantly suppressed 
the migratory, growth and adherence properties of the cells 
(p<0.01). By contrast, the knockdown of mtSS1 in du-145 
human prostate cancer cells dramatically enhanced these 
properties (p<0.001). We concluded that mtSS1 demonstrates 
the ability to play a role in controlling the metastatic nature of 
prostate cancer cells.
Introduction
prostate cancer is the second leading cause of cancer-related 
mortality in males in the uK, with 9,900 deaths each year, 
and it accounts for 13% of cancer-related deaths in males. 
approximately 85% of these cases involve men over 70 years 
of age. the mortality rate for prostate cancer peaked in the 
early 1990s and has now fallen to approximately 25 per 
100,000 individuals at risk. in the uK, the survival rates have 
been improving, and the 5-year relative survival rate was 60% 
in the period 1993 to 1995 (1). 
metastasis is a complex multi-step process by which 
primary tumour cells invade adjacent tissue, enter the systemic 
circulation (intravasate), translocate through the vasculature, 
arrest in distant capillaries, extravasate into the surrounding 
tissue parenchyma and finally proliferate from microscopic 
growths (micrometastases) into macroscopic secondary 
tumours. metastases can be located in various organs and 
in different regions of the same organ. the organ micro-
environment modifies the response of metastatic tumour cells 
to therapy and alters the effectiveness of anticancer agents in 
destroying the tumour cells without producing undesirable 
toxic effects. the major obstacle to treating metastasis is the 
biological heterogeneity of primary neoplasms and metastases. 
By the time of diagnosis, cancers contain multiple genetically 
unstable cell populations with diverse karyotypes, growth 
rates, cell-surface properties, antigenicities, immunogenici-
ties, marker enzymes, sensitivity to various cytotoxic drugs 
and abilities to invade and produce metastasis (2). 
angiogenesis plays a key role in the pathogenesis of a 
variety of disorders, including cancer, proliferative retin-
opathies and rheumatoid arthritis. accumulating evidence 
indicates that, for most tumours, the switch to an angiogenic 
phenotype depends upon the outcome of a balance between 
angiogenic stimuli and angiogenic inhibitors, both of which 
may be produced by tumour cells and perhaps by certain host 
cells (3). Growth and motility factors play an essential role in 
migration processes at various levels of the metastatic cascade. 
these factors include metastasis activators and suppressors, 
which act in autocrine or paracrine manners through special 
receptors that mediate different signals through tyrosine phos-
phorylation (4). however, metastasis suppressors may inhibit 
metastasis at any step of the metastatic cascade without 
blocking tumourigenicity (5).
metastasis tumour suppressor-1 (mtSS1), also known as 
Missing in Metastasis (MIM), was originally identified as 
a tumour suppressor since it is expressed in non-metastatic, 
but absent from metastatic, bladder cancer cells (6,7). it is 
expressed during development in muscles, kidneys and the 
liver (8,9). the mtSS1 gene encodes a 5.3-kb mrna, and 
it is a polypeptide of 356 amino acids with homology to the 
Wiscott-aldrich Syndrome protein family (6). the mim 
protein and mim-B, a much longer 759-amino acid protein 
whose c-terminus is identical to the 356 amino acids encoded 
by the mim gene (10), are cytoplasmic in location and have 
multidomain and scaffolding function (9). 
mim-B induces actin-rich protrusions resembling micro-
spikes and lamellipodia at the plasma membrane and promotes 
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disassembly of actin stress fibres. The actin cytoskeleton plays 
a key role in regulating essential cellular processes, such as 
endocytosis, cell migration, cytokinesis and various morphoge-
netic processes. in addition, mtSS1 enhances arp2/3-mediated 
actin polymerization through interactions with cortactin (11). it 
is thus involved in cell motility and morphogenesis, and studies 
suggest that further analysis of mtSS1 expression or inactiva-
tion in tissue samples may define a new candidate for use as a 
marker for primary tumours or metastasis (12). mtSS1 is also 
a member of the sonic hedgehog signalling pathway, which 
interacts and modulates Gli responses during cell growth and 
carcinogenesis (8). 
this study aimed to assess mtSS1 expression levels in 
prostate cancer cell lines in order to reveal any changes in cell 
properties and to clarify the cellular function of mtSS1 in 
these cancer cells. in the present study, we analysed mtSS1 
through a series of expression and inactivation studies to 
clarify the function of mtSS1 in prostate cancer cells.
Materials and methods
Cell lines and culture. the cells were routinely cultured 
with Dulbecco's modified Eagle's medium (DMEM) (PAA 
laboratories ltd., Somerset, uK) supplemented with 10% 
fetal calf serum (paa laboratories ltd.), penicillin and strep-
tomycin. this study used human prostate cancer (du-145, 
pc-3 and ca-hpV10) and human breast cancer (Zr-751 and 
mda-mB-231) cell lines. the cell lines were purchased from 
the american type culture collection (atcc, rockville, 
MD, USA) and were stored at 37˚C in 5% CO2 and under 95% 
humidity. 
RNA preparation and reverse transcription-polymerase 
chain reaction. total cellular rna was isolated from the 
homogenized human cell lines using total rna isolation 
reagent (advanced Biotechnologies ltd., Epsom, Surrey, 
uK). rna concentration and quality were determined 
through spectrophotometric measurement (Wpa uV 1101; 
Biotech photometer, cambridge, uK). cdna was gener-
ated using 200 ng of each rna sample and a transcription 
kit (Sigma, poole, dorset, uK) to reverse transcribe the 
RNA samples into cDNA. DNA quality was verified using 
Gapdh. mtSS1 mrna levels were assessed using mtSS1 
primers (sense, tcaaGaacaGatGGaaGaatGG; anti-
sense, tGcGGtaGcGGtaatGtG). pcr was carried out 
using a t-cy thermocycler (creacon technologies ltd., the 
netherlands) and rEdtaq® readymix™ pcr reaction mix 
(Sigma). the pcr conditions consisted of a 40-sec denatur-
ation step (95˚C), a 2-min annealing step (58˚C) and a 3-min 
elongation step (72˚C); elongation took place over 36 cycles. 
the pcr products were next loaded onto a 0.8% agarose gel 
and electrophoretically separated prior to being stained with 
ethidium bromide and visualised under uV light. 
Quantitative real-time polymerase chain reaction. Quantitative 
real-time polymerase chain reaction (Qpcr) is a technology 
that provides a broad dynamic range for detecting specific 
gene sequences with high sensitivity. to quantify the level of 
mtSS1 transcripts in the prostate cancer cell lines, the icycler 
iQ system (Biorad, camberley, uK) was used. cdna samples 
were examined for mtSS1 expression using the mtSS1 Qpcr 
primers (sense, atatcccaGGatGccttc; antisense, 
actGaacctGaccGtacacGGttctcGcttctcttt). 
The QPCR technique utilized the Amplifluor System™ 
(intergen inc., uK) and Q-pcr master mix (aBgene, Surrey, 
uK), in conjunction with a universal probe (uniprimer™). 
The real-time QPCR conditions were: 95˚C for 15 min, 
followed by 60 cycles at 95˚C for 20 sec, 55˚C for 30 sec and 
72˚C for 20 sec. 
Generation of ribozyme transgenes and MTSS1 knockdown 
cells. mtSS1 expression levels were reduced in the du-145 
prostate cancer cell line using a ribozyme system. Briefly, 
ribozyme transgenes that specifically cleave MTSS1 mRNA 
were designed based on the predicted secondary structure of 
mtSS1. these ribozymes were then generated using touchdown 
pcr and subsequently cloned into the pEF6/V5-his-topo 
vector and amplified in Escherichia coli. plasmids were 
purified and verified for correct size and orientation of the 
ribozymes, and electroporated into the du-145 prostate cancer 
cell line. a closed pEF6/V5/his-topo plasmid (containing no 
ribozyme sequence) was also electroporated into the same cell 
line to create a control group. after selection using blasticidin, 
the unaltered wild-type cells were termed du-145 Wt, the 
wild-type cells containing closed plasmid only were termed 
du-145 pEF and the wild-type cells containing plasmid with a 
ribozyme sequence were termed du-145 mtSSiKd.
Generation of MTSS1-overexpressing cell lines. the full 
sequence of MTSS1 was amplified from cDNA using the stan-
dard pcr procedure and a master mix with a proofreading 
enzyme (sense primer, atGGaGGctGtGattGaG; anti-
sense, ctaaGaaaaGcGaGGGG). this mtSS1 sequence 
was then t-a cloned into the pEF6/V5/his-topo vector 
(invitrogen, paisley, uK) and then electroporated into the 
pc-3 prostate cancer cell line with the aim of enhancing 
mtSS1 expression in a cell line that does not normally express 
it. multiple clones were used, assessed and sequenced. the 
pc-3 cells thus prepared and expressing mtSS1 were referred 
to in the study as pc-3 mtSS1Exp. the control group of cells 
contained the same plasmid vector (minus the mtSS1 
sequence) and was termed pc-3 pEF.
Confirmation of MTSS1 overexpression and knockdown by 
Western blotting. mtSS1 protein expression was assessed in 
the human prostate cancer cell line lysates through standard 
SdS-paGE and Western blot analysis. the cells were grown 
to confluence in a 75-cm2 tissue culture flask before being 
detached using a cell scraper and pelleted. the cell pellet was 
then lysed in hcmF buffer with 0.5% SdS, 1% triton x-100, 
2 mm cacl2, 100 µg/ml phenylmethylsulfonyl fluoride, 1 mg/
ml leupeptin, 1 mg/ml aprotinin and 10 mm sodium orthovana-
date on a rotor wheel for 1 h and spun at 13,000 x g for 15 min 
to remove insolubles. The lysed protein was then quantified 
using the Bio-rad dc protein assay kit (Bio-rad laboratories, 
CA, USA), and the samples were normalized to a standard final 
concentration of 1.5 mg/ml following addition of Sample Buffer, 
laemmli 2x concentrate (Sigma) in a 1:1 ratio. the samples 
were then boiled for 5 min before being loaded into a 10% poly-
acrylamide gel. Following electrophoresis, proteins were blotted 
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onto a hybond-c Extra nitrocellulose membrane (amersham 
Biosciences uK ltd., Bucks, uK), blocked in 10% milk and 
subjected to specific antibody probing. The anti-MTSS1 anti-
body (Sc-98376, Santa cruz Biotechnologies inc., Santa cruz, 
ca, uSa) was used to probe for mtSS1 at a concentration of 
1:500 and anti-Gapdh (Santa cruz Biotechnologies inc.) at a 
concentration of 1:500 for Gapdh. probing with the primary 
antibody was followed by probing with peroxidase-conju-
gated anti-rabbit (mtSS1) or anti-rabbit (Gapdh) antibody 
(Sigma) at a 1:1,000 concentration. the Supersignal West dura 
Extended duration substrate chemiluminescent system (perbio 
Science uK ltd., cramlington, uK) was then used to visualize 
the protein bands. Gapdh expression was used as an internal 
control (Santa cruz Biotechnologies, Santa cruz, ca, uSa). 
Protein expression was assessed and quantified using Uvitech 
analysis software (uvitech, cambridge, uK).
Tumour cell growth assay. The effects of the modification of 
mtSS1 expression on prostate cancer cell growth rates were 
assessed using an in vitro growth assay. the cells were seeded 
in triplicate into 96-well plates at a density of 3,000 cells/well. 
plates were then incubated for 1, 3 and 5 days. cell density 
was recorded after 1, 3 and 5 days by fixing cells in 4% form-
aldehyde, washing and staining with 0.5% (w/v) crystal violet. 
Following this, the crystal violet stain was extracted with 10% 
(v/v) acetic acid before reading the absorbance on a Bio-tek 
Elx800 multiplate reader (Bio-tek instruments inc., Vt, uSa).
Cell adhesion assay. the adhesive properties of the 
MTSS1-modified cells to an artificial basement membrane 
were quantified using the in vitro matrigel adhesion assay. 
du-145 Wt, du-145 pEF control and du-145 mtSS1Kd 
cells and pc-3 Wt, pc-3 pEF control and pc-3 mtSS1Exp 
prostate cancer cells were seeded at a density of 50,000/well (in 
triplicate) into a 96-well plate that had been previously coated 
with 5 µg of Matrigel artificial basement membrane. The cells 
were then incubated for 45 min to allow them to adhere before 
being subjected to vigorous washing (x4) in BSS to remove the 
non-adherent cells. The adherent cells were then fixed in 4% 
formaldehyde (v/v) and stained with 0.5% (w/v) crystal violet. 
the number of stained adherent cells was counted in several 
random fields (≤40 objective magnifications).
Wounding assay. the migratory properties of pc-3 and 
du-145 cells were assessed to determine the impact of the 
forced expression or knockout of mtSS1 on the invasive 
nature of these prostate cancer cells. cells at a density of 106  
were incubated in 10 ml of growth medium containing 100 µl 
of cytodex-2 beads (GE healthcare, cardiff, uK) for 3 h to 
allow the cells to adhere to the beads. the beads were then 
washed to remove non-adherent or dead cells and resuspended 
in 5 ml of medium. the cell/bead complex was then incubated 
in a 96-well plate overnight. Following incubation, the cells 
were washed with BSS, and cells that had migrated from the 
cytodex-2 beads and adhered to the base of the well were 
fixed in 4% formaldehyde (v/v), stained with 0.5% crystal 
violet (w/v) and counted under x40 objective magnification. At 
least five random fields were counted per well, and five dupli-
cate wells were set up per sample. the entire experimental 
procedure was repeated three independent times.
Statistical analysis. all in vitro experimentation was repeated 
at least three independent times. the results were assessed 
using a two-sample, two-tailed t-test and the minitab 14 
statistical package. the values presented represent the mean 
± SEM, and p≤0.05 was considered statistically signifi-
cant. In vivo data were analysed using a non-parametric 
mann-Whitney test, as the data did not follow a normal 
distribution.
Results
MTSS1 expression in human cancer cell lines and creation 
of prostate cancer cell sublines with differential patterns 
of MTSS1 expression. mtSS1 was found to be highly 
expressed in the du-145 and 3t3 prostate cancer cells and 
at moderate levels in the ca-hpV-10 prostate and Zr 75-1 
breast cancer cells, while the highly invasive prostate cancer 
cell line pc-3 showed little expression (Fig. 1a). the highly 
invasive pc-3 prostate cancer cell line was transfected 
with the mtSS1 expression vector. Following selection, an 
mtSS1-overexpressing subline was established (Fig. 1B-d). 
the du-145 prostate cancer cell line was also an appro-
priate candidate for knockdown as the low-invasive cell line 
expressed levels of mtSS1. anti-mtSS1 trangenes were used 
to knockdown mtSS1 expression in the du-145 cells, followed 
by the establishment of a new subline which expressed a low 
level of mtSS1 (Fig. 1B and c). 
Regulation of MTSS1 expression affects the rate of cell growth 
of prostate cancer cells
Knockdown of MTSS1 expression increases prostate 
cancer cell growth. this study found that the levels of mtSS1 
protein had an effect on the growth rate of cells. the effects 
of the suppression of mtSS1 expression on the growth of 
du-145 cells was examined following a 5-day incubation 
period using an in vitro cell growth assay. There was a signifi-
cant difference in the cell growth rate between the wild-type 
(du-145 Wt) and mtSS1-suppressed (du-145 mtSSiKd) 
cells. Suppression of mtSS1 expression was found to increase 
the cell growth rate (du-145 mtSSiKd compared to 
du-145 Wt cells; p=0.001) (Fig. 2a). 
Enhanced MTSS1 expression suppresses prostate cancer 
cell growth. the growth capacity of the prostate cancer 
cells following mtSS1 overexpression was examined and 
compared to the wild-type cells using an in vitro cell growth 
assay for PC-3 cell lines. A significant reduction in cell growth 
after 5 days following enhancement of mtSS1 expression was 
noted (pc-3 mtSS1Exp when compared to pc-3 Wt cells; 
p=0.002) (Fig. 2B).
MTSS1 influences the adhesive ability of prostate cancer 
cell lines. to identify and examine the adhesive nature of the 
prostate cancer cells to attach to a basement membrane, an 
adhesion assay was carried out (Fig. 3). the results obtained 
show a significant increase (DU-145 MTSSIKD compared 
to du-145 Wt cells; p=0.001) in the ability to adhere to a 
basement membrane (Fig. 3a, top panel), indicating that the 
knockdown of mtSS1 expression in this cell line resulted 
in a dramatic increase in the degree of adhesion. however, a 
significant reduction (p=0.0001) in adhesive ability was noted 
muStaFa et al:  mtSS-1 in proStatE cancEr cEllS160
when pc-3 mtSS1Exp cells were compared to pc-3 Wt cells 
(Fig. 3a, bottom panel).
MTSS1 has differential effects on the motile properties of 
the prostate cancer cell lines. the results revealed that the 
presence of MTSS1 had a significant impact on the motile 
nature of the prostate cancer cells (Fig. 3B). A significant 
increase (p=0.0001) was observed in motility between the 
du-145 mtSSiKd and du-145 Wt cells (Fig. 3B, top panel). 
however, forced expression of mtSS1 in the pc-3 cell line 
resulted in a dramatic reduction in the degree of motility 
(pc-3 mtSS1Exp compared to pc-3 Wt cells; p=0.002) 
(Fig. 3B, bottom).
the du-145 prostate cancer cells demonstrated motile 
properties in the wound closure motility assay; however, the 
absence of MTSS1 expression in these cells significantly 
increased cell migration to close the wound as compared 
to the du-145 Wt cells (p=0.001) (Fig. 4a). as shown 
in Fig. 4B, the presence of mtSS1 expression in the 
PC-3 MTSS1Exp cells significantly suppressed cell migra-
tion when compared to the extent of cell migration in the 
pc-3 Wt  cells (p=0.01).
Discussion
in the present study, we examined a possible association 
between the expression of the metastasis suppressor gene 
(mtSS1) and prostate tumour cell invasive behaviour. 
Supported by a series of cellular function tests, the present 
study indicates that mtSS1 acts as a powerful inhibitor to 
the aggressiveness of prostate cancer cells. our initial studies 
examined mtSS1 expression in a variety of human normal 
and cancer cell lines. We reported that cancer cell lines, 
du-145 and 3t3, expressed moderate levels of mttS1.
these cell lines are considered to be of a low/non-invasive 
nature. the aggressive cell lines, mda-mB-231 and pc-3, are 
negative for mtSS1 expression. this is of note since it may 
indicate that levels of mtSS1 expression are inversely corre-
lated with aggressiveness. This is reflected in our subsequent 
expression modification studies, in which we created two cell 
models, du-145 mtSSiKd and pc-3 mtSS1Exp, with a 
differential pattern of mtSS1 expression.
  A
  B
  C
  D
Figure 1. Expression of mtSS1 in cancer cells and creation of sublines of 
prostate cancer cells with differential expression of mtSS1. (a) rt-pcr 
analysis of mtSS1 mrna expression in different human cancer cell lines. 
mtSS1 was found to be highly expressed in du-145 and 3t3 prostate cancer 
cells and at moderate levels in the ca-hpV-10 prostate and Zr 75-1 breast 
cancer cell lines, while the highly invasive prostate cancer cell line pc-3 
exhibited no expression. (B) rt-pcr assessment of mtSS1 overexpression/
knockdown in the prostate cancer cell lines. mtSS1 was overexpressed in 
the pc-3 cell line, whereas the mtSS1 expression level was suppressed 
in DU-145 MTSSIKD cells. (C) Confirmation of MTSS1 protein levels by 
Western blotting. Results obtained at the mRNA level were confirmed at the 
protein level. (d) Quantitative-pcr assessment of mtSS1 overexpression. 
Quantification of MTSS1 transcripts in the PC-3 cell line verified the obser-
vations from the initial pcr data.
  A
  B
Figure 2. Growth assay demonstrating the effect of mtSS1 expression levels 
on prostate cancer cell growth after 5 days of incubation. (a) an increase in 
the du-145 mtSS1Kd cell growth rate was observed following the knock-
down of mtSS1 expression (p=0.001). (B) overexpression of mtSS1 in the 
PC-3 cells (PC-3 MTSS1Exp) resulted in a significant decrease in the cell 
growth rate (p=0.002).
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the invasive mtSS1-negative pc-3 cell line was ‘forced’ 
to overexpress mtSS1, while the non-invasive mtSS-positive 
du-145 cell line had its mtSS1 expression levels ‘knocked 
down’. We used a range of biological function assays in vitro 
to assess the affect of the modification of MTSS1 expression 
on the metastatic nature of these prostate cancer cell lines. our 
study provides evidence that the forced expression of mtSS1 
in the pc-3 prostate cancer cells greatly reduced the aggres-
sive nature of these cells by reducing their adhesive, growth 
and motile properties.
in contrast, the elimination of mtSS1 expression in the 
du-145 cells exhibited an inverse effect. this low-invasive 
cell line displayed significant increases in tumour cell migra-
tion, growth and adhesion. Therefore, our findings suggest that 
mtSS1 plays a key role in determining the metastatic nature 
of prostate cancer cells.
notably, parr et al (13) revealed that mtSS1 acts as an 
indicator for survival for breast cancer patients. they demon-
strated that patients expressing high levels of mtSS1 had a 
favourable prognosis in contrast to patients with low levels 
of mtSS1 expression who were associated with a poor prog-
nosis. utikal et al (12) suggested that the mechanism for the 
down-regulation of mtSS1 may involve dna methylation. 
overexpression of mtSS1 was found to enhance changes in 
cell shape, such as an increase in the formation of membrane 
ruffles and filopodia-like structures (7,10,14-16).
mtSS1 has been shown to be a metastatic suppressor 
in bladder cancer (6). in contrast, mtSS1 expression was 
found to be similar in metastatic cell lines (14) and basal cell 
carcinomas (9). this regulation suggests that mtSS1 levels 
are likely to be controlled during cell growth and develop-
ment, and that mtSS1 expression is altered in cancer cells, 
Figure 3. adhesion and cell motility assay demonstrating the effect of mtSS1 expression levels on prostate cancer cells. (a) Suppression of mtSS1 expres-
sion levels (du-145 mtSS1 Kd) enhanced the adhesive properties of the du-145 prostate cancer cell line (*p=0.001 vs. control). a reduction in the adhesive 
nature of the pc-3 cells was observed by the forced expression of mtSS1 (**p=0.0001 vs. control). (B) Suppression of mtSS1 in du-145 cells resulted in 
reduced motility (*p=0.0001). overexpression of mtSS1 in pc-3 cells led to decreased motility (p=0.002).
Figure 4. migration assay demonstrating the effect of mtSS1 expression levels on prostate cancer cells. (a) an increase in the cell motility rate of 
DU-145 MTSSIKD cells by the knockdown of MTSS1 expression. (B) Overexpression of MTSS1 in PC-3 cells significantly reduced the migration rate.
  A   B
  A   B
muStaFa et al:  mtSS-1 in proStatE cancEr cEllS162
leading to changes in the signalling and architecture of the 
cytoskeleton. 
one study reported that the down-regulation of mtSS1 
expression in bladder cancer may correlate with the transition 
of tumour cells from a distinct epithelium-like morphology to 
less differentiated carcinomas (17,18). another study found a 
dramatic increase in mtSS1 expression in normal liver speci-
mens compared to matched hepatocellular carcinoma tumour 
tissue specimens (18).
Elevated mtSS1 expression was observed in early stage 
disease, suggesting that mtSS1 plays a key role in promoting 
the early development of hepatocellular carcinoma and may 
therefore serve as a biomarker for the prediction of early 
tumour development of hepatocellular carcinoma. thus, it is 
likely that a metastasis suppressor for mtSS1 will be highly 
dependent upon tumour type (13).
in conclusion, our study indicates that mtSS1 is capable 
of modulating the metastatic ability in prostate cancer cells. 
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